Companies › Ocular Therapeutix
1 active drug program in 29 registered trials: 20 Phase 2, 6 Phase 3, 2 Phase 1, 1 Phase 4; Oncology, Ophthalmology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Axitinib Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 3 | Neovascular Age-related Macular Degeneration; Non-Proliferative Diabetic Retinopathy; Neovascular Age-Related Macular Degeneration; Neovascular Age-Related Macular Degeneration (nAMD) … | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03438708 | Axitinib | Phase 2 | Clear Cell Renal Cell Carcinoma | Oncology | Mar 2026 |
| NCT05808608 | Axitinib | Phase 1 | Renal Cell Carcinoma | Oncology | Apr 2026 |
| NCT03595124 | Axitinib | Phase 2 | Metastatic Renal Cell Carcinoma | Oncology | Nov 2026 |
| NCT02912572 | Axitinib | Phase 2 | Metastatic Endometrial Cancer | Oncology | Nov 2026 |
| NCT05768464 | Axitinib | Phase 2 | Non-clear Renal Cell Carcinoma | Oncology | Dec 2026 |
| NCT03297606 | Axitinib | Phase 2 | Lymphoma, Non-Hodgkin | Oncology | Dec 2026 |
| NCT03092856 | Axitinib | Phase 2 | Clear Cell Renal Cell Carcinoma | Oncology | Dec 2026 |
| NCT06495918 | Axitinib | Phase 3 | Neovascular Age-related Macular Degeneration | Ophthalmology | Jan 2027 |
| NCT03839498 | Axitinib | Phase 2 | Pheochromocytoma | Oncology | Jan 2027 |
| NCT06211114 | Axitinib | Phase 2 | Collecting Duct Carcinoma | Oncology | Feb 2027 |
| NCT06889649 | Axitinib | Phase 2 | Radiation Therapy | Oncology | Feb 2027 |
| NCT07235085 | Axitinib | Phase 3 | Non-Proliferative Diabetic Retinopathy | Ophthalmology | Mar 2027 |
| NCT04996823 | Axitinib | Phase 2 | Melanoma | Oncology | Mar 2027 |
| NCT05817903 | Axitinib | Phase 2 | Metastatic Renal Cell Carcinoma | Oncology | Apr 2027 |
| NCT03172754 | Axitinib | Phase 1 | Renal Cell Carcinoma | Oncology | Apr 2027 |
| NCT05384496 | Axitinib | Phase 2 | Mucosal Melanoma | Oncology | May 2027 |
| NCT07172386 | Axitinib | Phase 2 | Renal Cell Carcinoma (RCC) | Oncology | Jul 2027 |
| NCT06223958 | Axitinib | Phase 3 | Neovascular Age-Related Macular Degeneration | Ophthalmology | Sep 2027 |
| NCT06903312 | Axitinib | Phase 4 | Renal Cell Cancer | Oncology | Oct 2027 |
| NCT07123090 | Axitinib | Phase 2 | Metastatic Renal Cell Carcinoma | Oncology | Oct 2027 |
| NCT07744932 | Axitinib | Phase 2 | Oligometastatic Clear Cell Renal Cell Carcinoma | Oncology | Dec 2027 |
| NCT05738694 | Axitinib | Phase 3 | Renal Cell Carcinoma | Oncology | Dec 2027 |
| NCT05327686 | Axitinib | Phase 2 | Metastatic Renal Cell Carcinoma | Oncology | Jun 2028 |
| NCT06279403 | Axitinib | Phase 2 | Immune Checkpoint Inhibitors | Oncology | Jun 2028 |
| NCT04341181 | Axitinib | Phase 2 | Cancer | Oncology | Apr 2029 |
| NCT07469683 | Axitinib | Phase 2 | Clear Cell Renal Cell Carcinoma | Oncology | Oct 2029 |
| NCT05969496 | Axitinib | Phase 2 | Renal Cancer | Oncology | Nov 2029 |
| NCT07516132 | Axitinib | Phase 3 | Neovascular Age-Related Macular Degeneration (nAMD) | Ophthalmology | Aug 2030 |
| NCT04510597 | Axitinib | Phase 3 | Metastatic Clear Cell Renal Cell Carcinoma | Oncology | Jul 2033 |
Cash of $531m on 2026-09-30; operating cash outflow about $267m a year; runway about 24 months at that burn, to Sep 2028; 6 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Hutchmed Merck & Co. (MSD) Takeda AO GENERIUM Chipscreen Biosciences Avalyn Pharma Mannkind Betta Pharmaceuticals Criterium Chia Tai Tianqing Pharmaceutical Group
Immutep S.A.S. ADC Therapeutics Candel Therapeutics Actinium Pharmaceuticals GrandPharma (China)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.